NCT07416188 2026-03-18
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
Clinical Trials
189 trialsNCT06161519 2026-03-17
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05588141 2026-03-13
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05124912 2026-02-20
REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
Phase NA Recruiting
NCT07424092 2026-02-20
PED-DNX2401
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Not yet recruiting
NCT07263438 2026-02-13
Phenix
Centre Hospitalier Universitaire Vaudois
Phase 2 Recruiting
NCT05184816 2026-01-30
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05629702 2026-01-30
ARISTOCRAT
University of Birmingham
Phase 2 Recruiting
NCT06208657 2026-01-28
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2 Recruiting
NCT06193174 2026-01-22
Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
University of Alabama at Birmingham
Phase 1 Terminated
NCT04773782 2026-01-13
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
Phase 1/2 Completed
NCT07331064 2026-01-09
GABRIEL
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT04656535 2026-01-07
AB154 Combined With AB122 for Recurrent Glioblastoma
Yale University
Phase EARLY_PHASE1 Active not recruiting
NCT02650401 2025-12-24
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT02932280 2025-12-05
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT03233152 2025-11-21
GlitIpNi
Universitair Ziekenhuis Brussel
Phase 1/2 Active not recruiting
NCT07242963 2025-11-21
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study
Baylor College of Medicine
Recruiting
NCT05768880 2025-11-20
Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT03557359 2025-11-03
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
Phase 2 Completed
NCT05366179 2025-10-20
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
NCT05634707 2025-09-22
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
Duke University
Phase EARLY_PHASE1 Active not recruiting
NCT03561870 2025-09-12
OLAGLI
Hospices Civils de Lyon
Phase 2 Completed
NCT03970447 2025-09-09
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT03672721 2025-08-11
IA Carboplatin + Radiotherapy in Relapsing GBM
Université de Sherbrooke
Phase 1/2 Recruiting
NCT06356883 2025-08-07
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
Université de Sherbrooke
Phase 2 Recruiting
NCT06430424 2025-07-30
GBrecurr
University Hospital, Bordeaux
Recruiting
NCT01370330 2025-07-22
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
University of California, San Francisco
Available
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT02766699 2025-06-03
CerebralEDV
Engeneic Pty Limited
Phase 1 Completed
NCT05432518 2025-04-25
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Phase EARLY_PHASE1 Recruiting
NCT05900908 2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4 Withdrawn
NCT06674265 2025-04-09
Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma
Kian Immune Cell Company
Phase 1 Recruiting
NCT03690869 2025-04-08
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT06721689 2025-03-26
PEEL-224
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT01822652 2025-02-24
GRAIN
Baylor College of Medicine
Phase 1 Active not recruiting
NCT02298348 2025-02-17
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT06751134 2025-02-07
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Nanjing Children's Hospital
Phase 1 Recruiting
NCT06801730 2025-01-30
NALIRIBVRG
The Central Hospital of Lishui City
Phase 2 Recruiting
NCT04758533 2024-12-27
AloCELYVIR
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Phase 1/2 Active not recruiting
NCT06684639 2024-12-20
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
The General Hospital of Western Theater Command
Phase EARLY_PHASE1 Recruiting
NCT04908176 2024-12-13
A Drug-drug Interaction Study of Avapritinib and Midazolam
Blueprint Medicines Corporation
Phase 1 Completed
NCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing
NCT03075072 2024-10-23
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
Dana-Farber Cancer Institute
Phase NA Active not recruiting